Royalty Pharma plc — Form SCHEDULE 13D/A
Filed August 17, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 18/100
What the filing says
Pablo G. Legorreta filed an amended Schedule 13D/A regarding beneficial ownership in Royalty Pharma plc. The filing header and metadata are present but the substantive amendment details—specific shareholding changes, percentages, counterparties, or dollar amounts—are not disclosed in the provided text. No concrete ownership changes can be identified from this excerpt.
Why this rating
Schedule 13D/A is routine disclosure. Without disclosed shareholding %, amounts, or material transaction details, this appears administrative amendment. Cannot assess materiality absent specifics.
See more from August 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.